FDA accepts Intellipharmaceutics ANDA filing

The FDA has accepted for filing an abbreviated new drug application for a generic version of Seroquel XR tablets from Intellipharmaceutics International (NASDAQ:IPCI; TSX:I), which now has five ANDAs awaiting approval. Seroquel XR is an oral psychotropic agent indicated for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Sales of Seroquel XR in the [...]

Intellipharmaceutic files ANDA for generic SEROQUEL XR

Intellipharmaceutics International (Nasdaq:IPCI; TSX:I) has submitted an abbreviated new drug application with the FDA for a generic of Seroquel XR, an oral psychotropic agent indicated for the treatment of schizophrenia, bipolar disorder and major depressive disorder. Sales of Seroquel XR in the U.S. were about $823-million in 2010. “The filing of a generic version of Seroquel XR [...]

Intellipharmaceutics hires Doll to commercialize drugs

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has retained Doll Consulting and its principal, David Doll, to assist the company with the commercialization of products in its controlled-release generic drug and NDA portfolios. “We now have four products filed with the FDA for the purpose of obtaining regulatory approval in the U.S. – ANDA’s for Focalin XR, Effexor [...]

Intellipharmaceutics Files ANDA with FDA

Intellipharmaceutics International (NASDAQ:IPCI;TSX:I) has filed an abbreviated new drug application with the FDA for approval to market a generic version of the 30-mg strength of Focalin XR for the treatment of Attention Deficit Hyperactivity Disorder. The application for the 30-mg strength is filed as an amendment to the ANDA that Intellipharmaceutics had previously filed for [...]

FDA accepts Intellipharmaceutics ANDA for generic Protonix

The FDA has accepted Intellipharmaceutics International’s (Nasdaq:IPCI; TSX:I) abbreviated new drug application for a generic version of Protonix, a delayed release pantoprazole sodium,which inhibits gastric acid secretion. The drug is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

Intellipharmaceutics CEO moulded at Biovail U

Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF; TSX:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s Adalat CC, Pfizer’s Procardia XL and Novartis’ Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI; TSX:I) as we had at Biovail,” Dr. Odidi says in an exclusive interview with [...]